Takeda, Y <br/><br/>
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.  [electronic resource] 

 -  British journal of cancer  Dec 2005 
 - 1341-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0007-0920 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6602866  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antacids--administration & dosage<br/>Antidiarrheals--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Area Under Curve<br/>Camptothecin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cholagogues and Choleretics--administration & dosage<br/>Cisplatin--administration & dosage<br/>Diarrhea--chemically induced<br/>Disease Progression<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Irinotecan<br/>Lung Neoplasms--drug therapy<br/>Magnesium Oxide--administration & dosage<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Sodium Bicarbonate--administration & dosage<br/>Survival Analysis<br/>Ursodeoxycholic Acid--administration & dosage